Home › Research › Mild cognitive impairment
Blood biomarkers of Alzheimer’s disease and progression across different stages of cognitive decline in the community
Martina Valletta, Davide Liborio Vetrano, Caterina Gregorio, Debora Rizzuto, Bengt G. Winblad, Marco Canevelli, Sarah Wamala Andersson, Matilda Dale et al.. Nature Communications, 2025-11-23
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Blood biomarkers of Alzheimer's disease (AD) are promising for dementia prediction, but their association with progression across intermediate stages of cognitive decline in the general population remains unclear. We followed 2148 dementia-free individuals from a Swedish population-based cohort for up to 16 years. Associations between baseline AD blood biomarkers and transitions between normal cognition, mild cognitive impairment (MCI), and dementia were examined. Lower amyloid-β42/40 ratio and higher phosphorylated-tau181 (p-tau181), p-tau217, total-tau, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were associated with faster progression from MCI to all-cause and AD dementia, with the strongest associations for NfL and p-tau217. Elevated NfL and GFAP were linked to reduced MCI reversion to normal cognition, whereas no biomarker was associated with MCI development from normal cognition. These findings show robust group-level associations and indicate that AD blood biomarkers may help stratify dementia risk at the MCI stage in the community.
What this study adds
Evidence grade: Moderate
This population-based cohort study found that several blood biomarkers were associated with faster progression from mild cognitive impairment to dementia, while no biomarker was associated with developing mild cognitive impairment from normal cognition. It suggests biomarkers may help stratify risk at the mild cognitive impairment stage but does not test any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Valletta, M., Vetrano, D. L., Gregorio, C., Rizzuto, D., Winblad, B. G., Canevelli, M., et al. (2025). Blood biomarkers of Alzheimer’s disease and progression across different stages of cognitive decline in the community. Nature Communications. https://doi.org/10.1038/s41467-025-66728-2
Vancouver
Valletta M, Vetrano DL, Gregorio C, Rizzuto D, Winblad BG, Canevelli M, et al. Blood biomarkers of Alzheimer’s disease and progression across different stages of cognitive decline in the community. Nature Communications. 2025. doi:10.1038/s41467-025-66728-2. PMID: 41276530.
BibTeX
@article{valletta2025-41276530,
author = {Valletta, Martina and Vetrano, Davide Liborio and Gregorio, Caterina and Rizzuto, Debora and Winblad, Bengt G. and Canevelli, Marco and Andersson, Sarah Wamala and Dale, Matilda and others},
title = {{Blood biomarkers of Alzheimer’s disease and progression across different stages of cognitive decline in the community}},
journal = {Nature Communications},
year = {2025},
doi = {10.1038/s41467-025-66728-2},
pmid = {41276530},
url = {https://doi.org/10.1038/s41467-025-66728-2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Lower amyloid-β42/40 ratio and higher phosphorylated-tau181 (p-tau181), p-tau217, total-tau, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were associated with faster progression from MCI to all-cause and AD dementia, with the strongest associations for NfL and p-tau217.
- Elevated NfL and GFAP were linked to reduced MCI reversion to normal cognition, whereas no biomarker was associated with MCI development from normal cognition.
- These findings show robust group-level associations and indicate that AD blood biomarkers may help stratify dementia risk at the MCI stage in the community.
Why it matters
This population-based cohort study found that several blood biomarkers were associated with faster progression from mild cognitive impairment to dementia, while no biomarker was associated with developing mild cognitive impairment from normal cognition. It suggests biomarkers may help stratify risk at the mild cognitive impairment stage but does not test any treatment, cure, or prevention.
Study details
- Evidence strengthModerate
How this study scored 52/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Nature Communications) |
| Journal's citation record | 4 / 4 | Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 25 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 15.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 25 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Giulia Grande: h-index 38 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Karolinska Institutet: institution h-index 1,477 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41276530) |
| Free to read | 2 / 2 | Free to read |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41467-025-66728-2
- PubMed: 41276530
- Original source →
- Free full text: Nature Communications →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Mild cognitive impairment from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.